PRINCETON, N.J., Sept. 16, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, is pleased to invite investors to a webinar on September 18, 2024, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, Inc., will feature Soligenix President and Chief Executive Officer, Christopher J. Schaber, PhD, who will share insight ...

Active Ingredient in HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma PRINCETON, N.J., Sept. 3, 2024 /PRNewswire/ -- Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the European Patent Office has granted the patent entitled "Systems and Methods for Producing Synthetic Hypericin". The newly issued patent's claims are dire ...

PRINCETON, N.J., Aug. 9, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended June 30, 2024. "This is a pivotal time for Soligenix with a great deal of clinical activity and upcoming milestones," stated Christopher J. Schaber, PhD, President and C ...

Future Directions: Looking ahead, Dr. Kim highlighted upcoming milestones, saying, "In the short term, we expect to issue results from the IIS as data warrants... Additionally, these initial results are very exciting and build upon the increasing body of positive HyBryte™ data as we move into the 18-week confirmatory FLASH2 study later this year." PRISM MarketView does not provide investment advice. M PRISM M MarketView Highlights from the Q&A: About Soligenix recommendation of any security. PCG may be comp ...

NEW YORK, July 15, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView is pleased to announce an exclusive Q&A session with Dr. Ellen Kim, discussing the promising interim results of Soligenix's (Nasdaq:SNGX) HyBryte™ from the ongoing investigator-initiated study (IIS). HyBryte™ (synthetic hypericin) is a novel photodynamic therapy for the treatment of early-stage cutaneous T-cell lymphoma (CTCL), a rare form of non-Hodgkin's lymphoma with no FDA-approved first-line treatments. Highlights from the Q&A: Promising Inte ...

Soligenix Inc. NASDAQ: SNGX, a late-stage biopharmaceutical company, experienced an astonishing surge Tuesday. At the time of writing, the stock had soared nearly 400%. This dramatic increase, accompanied by a substantial rise in trading volume, warrants a closer look at the catalyst behind this movement and the company's fundamentals. This surge comes amidst increasing interest in small-cap stocks, which have seen a resurgence lately. Summer trading favors volatile market moves in low float names and has d ...

Shares of Soligenix (NASDAQ:SNGX) are surging higher by over 300% following an update on the biopharmaceutical company's study of its HyBryte treatment. HyBryte focuses on patients with early-stage cutaneous T-cell lymphoma (CTCL). According to the press release: "Patients have responded positively to HyBryte™ therapy with 75% (3 of the 4 subjects who have completed at least 12 weeks of therapy) already achieving "Treatment Success", as predefined in the study's protocol as ≥50% improvement in their cumulat ...

Loading... U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining more than 50 points on Tuesday. Check This Out: Nvidia To Rally Over 40%? Here Are 10 Top Analyst Forecasts For Tuesday Information technology shares jumped by 0.8% on Tuesday. Top Headline Equities Trading UP Equities Trading DOWN Also Check This Out: How To Earn $500 A Month From PepsiCo Stock Ahead Of Q2 Earnings In commodity news, oil traded down 1% to $81.53 while gold traded up 0.1% at $2,366.50. Euro zone As ...

Core Insights - HyBryte therapy has shown positive responses in patients, with three out of four subjects achieving "Treatment Success" after at least 12 weeks of treatment [2][9] - The Phase 3 FLASH study demonstrated the efficacy and promising safety profile of HyBryte, addressing the limited treatment options for early-stage cutaneous T-cell lymphoma (CTCL) patients [4][10] - The interim update from Soligenix indicates ongoing collaboration with the FDA for further studies, including a confirmatory Phase 3 placebo-controlled study [6] Study Details - The open-label study (protocol HPN-CTCL-04) enrolled ten patients, with six patients treated for up to 44 weeks [3][13] - Initial results from the expanded use of HyBryte in a real-world setting were described as "promising," supporting previous positive Phase 2 and 3 clinical trial results [10] - Two of the three patients who achieved Treatment Success did so within the first 12 weeks, while the third achieved success at 18 weeks [9] Efficacy and Safety - The study revealed that 60% of patients treated with HyBryte achieved a 50% or better improvement in their mCAILS score, compared to 20% of patients treated with Valchlor [11] - HyBryte has been reported to have a favorable safety profile, with no treatment-related adverse events observed in all patients [14] Market Reaction - Following the positive news, Soligenix Inc (SNGX) shares surged by 221.5%, reaching $6.43, with a trading volume of 23.6 million shares [7][8]

Group 1 - Soligenix (NASDAQ:SNGX) stock has surged by 296% following positive data from its late-stage HyBryte treatment for early-stage cutaneous T-cell lymphoma (CTCL) [4][5] - In a 12-month study, six patients were enrolled, with four patients achieving a 50% improvement in their cumulative mCAILS score compared to baseline after at least 12 weeks of treatment [1][6] - Heavy trading activity was noted, with over 46 million SNGX shares changing hands, significantly above the daily average of approximately 222,000 shares [2] Group 2 - The company anticipates improved outcomes for patients with continued treatment and plans to embark on a confirmatory Phase 3 replication study later this year [5] - The interim data indicates that one patient has shown significant improvement over 18 weeks, contributing to the overall positive outlook for the therapy [1][6]